
Tamas Alexy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1620061/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kidney Allograft and Recipient Survival After Heart Transplantation by Induction Type in the United States. Transplantation, 2022, 106, 633-640.	1.0	5
2	Axillary or Subclavian Impella 5.0 Support in Cardiogenic Shock: A Systematic Review and Meta-analysis. ASAIO Journal, 2022, 68, 233-238.	1.6	2
3	Fulminant myocarditis following coronavirus disease 2019 vaccination: a case report. European Heart Journal - Case Reports, 2022, 6, ytac007.	0.6	9
4	From the Other Side of the Exam Room: Using the New Universal Definition and Classification of Heart Failure to Engage Patients and Caregivers. Journal of Cardiac Failure, 2022, , .	1.7	0
5	Dystrophic Cardiomyopathy and the Need for Cardiovascular Care. Journal of Cardiac Failure, 2022, 28, 1040-1041.	1.7	1
6	COVID-19-Associated Myocarditis: An Evolving Concern in Cardiology and Beyond. Biology, 2022, 11, 520.	2.8	8
7	Dystrophic cardiomyopathy and patients with muscular dystrophies. Journal of Cardiac Failure, 2022, ,	1.7	0
8	Navigating Early Careers in Heart Failure in the Era of Novel Coronavirus Disease-2019. Journal of Cardiac Failure, 2021, 27, 97-99.	1.7	2
9	Designing a patientâ€specific search of transplant program performance and outcomes: Feedback from heart transplant candidates and recipients. Clinical Transplantation, 2021, 35, e14183.	1.6	5
10	A case of AL amyloidosis presenting with refractory ventricular fibrillation. Respiratory Medicine Case Reports, 2021, 32, 101349.	0.4	0
11	Outflow graft obstruction after left ventricular assist device implantation: a retrospective, singleâ€centre case series. ESC Heart Failure, 2021, 8, 2349-2353.	3.1	15
12	Heart Failure Care Delivery in the COVID-19 Era: The Patients' Perspective. Healthcare (Switzerland), 2021, 9, 245.	2.0	2
13	Overview of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiogenic Shock. Frontiers in Cardiovascular Medicine, 2021, 8, 686558.	2.4	55
14	First Successful LVAD Implantation After BioVentrix Revivent TC Ventricular Reshaping. Annals of Thoracic Surgery, 2021, 112, e123-e126.	1.3	3
15	Cardiac Transplantation and the Use of Cannabis. Life, 2021, 11, 1063.	2.4	1
16	Rapidly Progressive Left Ventricular Assist Device Outflow Graft Thrombosis Associated With COVID-19 Infection. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008334.	3.9	4
17	PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. American Heart Journal, 2020, 230, 35-43.	2.7	8
18	Nonsustained ventricular tachycardia in heart failure with preserved ejection fraction. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1126-1131.	1.2	14

#	Article	lF	CITATIONS
19	Donor Quality by UNOS Status After the 2018 Cardiac Transplantation Allocation System Change. Journal of Cardiac Failure, 2020, 26, S138-S139.	1.7	0
20	Update on COVID-19 Myocarditis. Medicina (Lithuania), 2020, 56, 678.	2.0	41
21	Hypotensive Response on Cardiopulmonary Stress Test is Associated with Increased One Year Mortality After Continuous Flow Left Ventricular Assist Device Implantation. Journal of Cardiac Failure, 2020, 26, S140-S141.	1.7	0
22	Ventricular Assist Device Driveline Dressing-Change Protocols: A Need for Standardization. A Report from the SimVAD Investigators. Journal of Cardiac Failure, 2019, 25, 695-697.	1.7	7
23	Association between angiotensin II antagonism and gastrointestinal bleeding on left ventricular assist device support. Journal of Heart and Lung Transplantation, 2019, 38, 469-471.	0.6	9
24	Emerging Therapies for DystrophicÂCardiomyopathy. JACC Basic To Translational Science, 2019, 4, 792-794.	4.1	1
25	Furosemide Reimagined. JACC: Heart Failure, 2018, 6, 71-72.	4.1	1
26	Neurological complications associated with left ventricular assist device therapy. Expert Review of Cardiovascular Therapy, 2018, 16, 909-917.	1.5	12
27	The role of blood rheology in sickle cell disease. Blood Reviews, 2016, 30, 111-118.	5.7	142
28	Abnormal blood rheology and chronic low grade inflammation: Possible risk factors for accelerated atherosclerosis and coronary artery disease in Lewis negative subjects. Atherosclerosis, 2015, 239, 248-251.	0.8	13
29	Gender differences in hemorheological parameters and in in vitro platelet aggregation in acetylsalicylic acid and clopidogrel treated vascular patients. Biorheology, 2014, 51, 197-206.	0.4	6
30	EPO or PlacEPO? Science versus Practical Experience. Biorheology, 2014, 51, 83-90.	0.4	11
31	TNF-α alters the release and transfer of microparticle-encapsulated miRNAs from endothelial cells. Physiological Genomics, 2014, 46, 833-840.	2.3	62
32	Shear sensitive microRNAs and atherosclerosis. Biorheology, 2014, 51, 147-158.	0.4	5
33	Effect of lanthanides on red blood cell deformability and response to mechanical stress: Role of lanthanide ionic radius. Biorheology, 2011, 48, 173-183.	0.4	7
34	In Patients with Sickle Cell Disease on Chronic Transfusion Therapy, Viscosity and Aggregation Are Increased After a Single Transfusion, Negatively Affecting Low Shear Rate Blood Flow. Blood, 2011, 118, 1259-1259.	1.4	0
35	Regulated Expansion of Human Pancreatic Î ² -Cells. Molecular Therapy, 2010, 18, 1389-1396.	8.2	4
36	A Novel High-Throughput Screening Assay for Sickle Cell Disease Drug Discovery. Journal of Biomolecular Screening, 2009, 14, 330-336.	2.6	7

#	Article	IF	CITATIONS
37	Comparison of three instruments for measuring red blood cell aggregation. Clinical Hemorheology and Microcirculation, 2009, 43, 283-298.	1.7	46
38	Parameterization of red blood cell elongation index – shear stress curves obtained by ektacytometry. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 777-788.	1.2	121
39	Comparison of three commercially available ektacytometers with different shearing geometries. Biorheology, 2009, 46, 251-264.	0.4	74
40	Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease. Haematologica, 2009, 94, 1060-1065.	3.5	141
41	Transfusion Therapy Decreases Oxygen Transport to Low-Flow Vascular Beds in Sickle Cell Disease Blood, 2009, 114, 1518-1518.	1.4	0
42	Microcirculatory Dysfunction in Cardiac Syndrome X: Role of Abnormal Blood Rheology. Microcirculation, 2008, 15, 451-459.	1.8	36
43	Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia. Journal of Vascular Surgery, 2008, 48, 377-381.	1.1	6
44	Hemorheological abnormalities in stable angina and acute coronary syndromes. Clinical Hemorheology and Microcirculation, 2008, 39, 43-51.	1.7	13
45	Relation of platelet aggregation and fibrinogen levels to advancing age in aspirin- and thienopyridine-treated patients. Clinical Hemorheology and Microcirculation, 2008, 40, 295-302.	1.7	3
46	Effects of cyclodextrins on RBC aggregation and blood viscosity. Clinical Hemorheology and Microcirculation, 2007, 36, 173-80.	1.7	3
47	Red blood cell aggregation quantitated via Myrenne aggregometer and yield shear stress. Biorheology, 2007, 44, 29-35.	0.4	22
48	Effect of lanthanum on red blood cell deformability. Biorheology, 2007, 44, 361-73.	0.4	4
49	Heparin-PF4 Antibodies Are Frequent after Vascular Surgery, but Not a Frequent Cause of Graft Thrombosis or Thrombocytopenia Blood, 2006, 108, 1491-1491.	1.4	0
50	An Unusual Form of Immune Thrombocytopenic Purpura Characertized by a Platelet Activating IgG Antibody Blood, 2006, 108, 1086-1086.	1.4	0
51	Estimation of infused dextran plasma concentration via measurement of plasma viscosity. Biorheology, 2006, 43, 161-6.	0.4	1
52	Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clinical Hemorheology and Microcirculation, 2006, 35, 139-42.	1.7	17
53	Glycoprotein IIIA Gene (PIA) Polymorphism and Aspirin Resistance: Is There Any Correlation?. Annals of Pharmacotherapy, 2005, 39, 1013-1018.	1.9	59
54	Measurement of whole blood viscosity profiles via an automated viscometer: technical details and clinical relevance. Clinical Laboratory, 2005, 51, 523-9.	0.5	12

#	Article	IF	CITATIONS
55	Short-Term Effect of Low-Dose Atorvastatin on Haemorrheological Parameters, Platelet Aggregation and Endothelial Function in Patients with Cerebrovascular Disease and Hyperlipidaemia. CNS Drugs, 2004, 18, 165-172.	5.9	45
56	Effects of PACAP on in vitro and in vivo neuronal cell death, platelet aggregation, and production of reactive oxygen radicals. Regulatory Peptides, 2004, 123, 51-59.	1.9	33
57	Inhibition of ADP-Evoked Platelet Aggregation by Selected Poly(ADP-Ribose) Polymerase Inhibitors. Journal of Cardiovascular Pharmacology, 2004, 43, 423-431.	1.9	9
58	Hemorheological methods in drug research. Clinical Hemorheology and Microcirculation, 2004, 30, 243-52.	1.7	1
59	In Vitro Antioxidant Properties of Pentoxifylline, Piracetam, and Vinpocetine. Clinical Neuropharmacology, 2002, 25, 37-42.	0.7	78
60	Scavenger Effect of Experimental and Clinically Used Cardiovascular Drugs. Journal of Cardiovascular Pharmacology, 2001, 38, 745-753.	1.9	23
61	Extracorporeal Life Support for Cardiac Arrest and Cardiogenic Shock. US Cardiology Review, 0, 15, .	0.5	2